Literature DB >> 19844808

Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease.

Rafael Fernandez-Montesinos1, Manuel Torres, David Baglietto-Vargas, Antonia Gutierrez, Illana Gozes, Javier Vitorica, David Pozo.   

Abstract

A major determinant in the pathogenesis of Alzheimer's disease (AD) is the deposition of beta-amyloid (Abeta) peptides in specific areas of the central nervous system. Therefore, animal models of Alzheimer amyloidosis are excellent tools to identify candidates to facilitate drug screening and to understand the molecular pathology of AD. Activity-dependent neuroprotective protein (ADNP) plays an essential role in brain development, and NAP (NAPVSIPQ, generic name: davunetide)--a peptide derived from ADNP--is currently in clinical development for the treatment of neurodegenerative disorders. However, the link between ADNP expression and AD remains unexplored. To test whether ADNP is affected by the onset of AD and progression, we employed the PS1xAPP mouse model (PS1(M146L) x APP(751SL) transgenic mice) to analyze the mRNA expression of ADNP in the hippocampus and cerebellum in early and advanced stages of disease. Results showed that ADNP expression in 6-month-old PS1xAPP mice hippocampus was higher than in wild-type (WT) mice. ADNP was originally identified as a vasoactive intestinal peptide (VIP)-responsive gene taking part in the VIP-mediated neurotrophic pathway. Interestingly, the expression of VIP was not affected in the same experimental setting, suggesting that ADNP expression is a VIP-independent marker associated with AD. Moreover, in the cerebellum, a brain area not affected by Abeta deposition, ADNP mRNA expression in 6-month-old PS1xAPP and WT were not different. A similar extent of hippocampal ADNP expression was observed in 18-month-old WT and PS1xAPP mice, in contrast to the differential expression level at 6 months of age. However, hippocampal ADNP expression in both WT and PS1xAPP was increased with aging similar to VIP mRNA expression. Our findings support the hypothesis that ADNP expression is related to early or mild AD progression by a VIP-independent mechanism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19844808     DOI: 10.1007/s12031-009-9300-x

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  40 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Recruitment of adult-generated neurons into functional hippocampal networks contributes to updating and strengthening of spatial memory.

Authors:  Stéphanie Trouche; Bruno Bontempi; Pascal Roullet; Claire Rampon
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-25       Impact factor: 11.205

3.  Neuroscience: The plaque plan.

Authors:  Alison Abbott
Journal:  Nature       Date:  2008-11-13       Impact factor: 49.962

4.  Vasoactive intestinal peptide gene expression from embryos to aging rats.

Authors:  I Gozes; P Schächter; Y Shani; E Giladi
Journal:  Neuroendocrinology       Date:  1988-01       Impact factor: 4.914

5.  The influence of the peptide NAP on Mac-1-deficient mice following closed head injury.

Authors:  Roy Zaltzman; Alexander Alexandrovich; Victoria Trembovler; Esther Shohami; Illana Gozes
Journal:  Peptides       Date:  2005-04-15       Impact factor: 3.750

6.  Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL.

Authors:  Miri Holtser-Cochav; Inna Divinski; Illana Gozes
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

7.  Progressive age-related impairment of cognitive behavior in APP23 transgenic mice.

Authors:  P H Kelly; L Bondolfi; D Hunziker; H-P Schlecht; K Carver; E Maguire; D Abramowski; K-H Wiederhold; C Sturchler-Pierrat; M Jucker; R Bergmann; M Staufenbiel; B Sommer
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

8.  Somatostatin and vasoactive intestinal polypeptide in postmortem brains from patients with Alzheimer-type dementia.

Authors:  H Arai; T Moroji; K Kosaka
Journal:  Neurosci Lett       Date:  1984-11-23       Impact factor: 3.046

9.  A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease.

Authors:  Yasuji Matsuoka; Yan Jouroukhin; Audrey J Gray; Li Ma; Chiho Hirata-Fukae; Hui-Fang Li; Li Feng; Laurent Lecanu; Benjamin R Walker; Emmanuel Planel; Ottavio Arancio; Illana Gozes; Paul S Aisen
Journal:  J Pharmacol Exp Ther       Date:  2008-01-16       Impact factor: 4.030

10.  Alzheimer's-type amyloidosis in transgenic mice impairs survival of newborn neurons derived from adult hippocampal neurogenesis.

Authors:  Laure Verret; Joanna L Jankowsky; Guilian M Xu; David R Borchelt; Claire Rampon
Journal:  J Neurosci       Date:  2007-06-20       Impact factor: 6.167

View more
  13 in total

Review 1.  Transcriptional Effects of ApoE4: Relevance to Alzheimer's Disease.

Authors:  Veena Theendakara; Clare A Peters-Libeu; Dale E Bredesen; Rammohan V Rao
Journal:  Mol Neurobiol       Date:  2017-09-06       Impact factor: 5.590

2.  Neurotrophic Peptides: Potential Drugs for Treatment of Amyotrophic Lateral Sclerosis and Alzheimer's disease.

Authors:  Jessica Ciesler; Youssef Sari
Journal:  Open J Neurosci       Date:  2013-04-08

3.  Vitamin D-binding protein interacts with Aβ and suppresses Aβ-mediated pathology.

Authors:  M Moon; H Song; H J Hong; D W Nam; M-Y Cha; M S Oh; J Yu; H Ryu; I Mook-Jung
Journal:  Cell Death Differ       Date:  2012-12-21       Impact factor: 15.828

Review 4.  Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics.

Authors:  Yahui Liu; Hong Qing; Yulin Deng
Journal:  Int J Mol Sci       Date:  2014-05-06       Impact factor: 5.923

5.  Therapeutic perspectives of drugs targeting Toll-like receptors based on immune physiopathology theory of Alzheimer's disease.

Authors:  Andrew R Schneider; Youssef Sari
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

6.  Direct Transcriptional Effects of Apolipoprotein E.

Authors:  Veena Theendakara; Clare A Peters-Libeu; Patricia Spilman; Karen S Poksay; Dale E Bredesen; Rammohan V Rao
Journal:  J Neurosci       Date:  2016-01-20       Impact factor: 6.167

7.  Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers.

Authors:  Anna Malishkevich; Gad A Marshall; Aaron P Schultz; Reisa A Sperling; Judith Aharon-Peretz; Illana Gozes
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

8.  Tau and caspase 3 as targets for neuroprotection.

Authors:  Anat Idan-Feldman; Regina Ostritsky; Illana Gozes
Journal:  Int J Alzheimers Dis       Date:  2012-05-30

9.  Reduction of aluminum ion neurotoxicity through a small peptide application - NAP treatment of Alzheimer's disease.

Authors:  Ming-Hui Yang; Shih-Cheng Chen; Yu-Fen Lin; Yi-Chia Lee; Ming-Yii Huang; Ko-Chin Chen; Hsin-Yi Wu; Po-Chiao Lin; Illana Gozes; Yu-Chang Tyan
Journal:  J Food Drug Anal       Date:  2019-01-12       Impact factor: 6.157

10.  Novel marker for the onset of frontotemporal dementia: early increase in activity-dependent neuroprotective protein (ADNP) in the face of Tau mutation.

Authors:  Yulie Schirer; Anna Malishkevich; Yotam Ophir; Jada Lewis; Eliezer Giladi; Illana Gozes
Journal:  PLoS One       Date:  2014-01-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.